HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums results

This article was originally published in The Rose Sheet

Executive Summary

Lanvin fragrance brand's $35 mil. sales in 2005 "far exceeded our expectations," driven more by "growing recognition and prestige" of the label than new products, Inter Parfums CEO Jean Madar says during March 9 earnings call. Net sales during the year soared 16% to $273.5 mil. Prestige product sales rose 22%, while mass market revenues dropped 18%. Net income was down 3% to $15.3 mil., firm adds. In Q4, net sales grew 3% to $65.7 mil., and net income advanced 11% to $3.9 mil. Separately, Inter Parfums announces extension of personal care deal with Gap Inc. to include developing products for Gap Outlet and Banana Republic Factory stores. New items are scheduled to be in outlet/factory stores by holiday, with additional products rolling out next year, firm says. Inter Parfums also will assume manufacturing and inventory management of existing personal care lines in those doors, company adds. Firm unveiled plans to create personal care for Gap and Banana Republic retail stores last July (1"The Rose Sheet" July 25, 2005, p. 3)...

You may also be interested in...



Inter Parfums Fills Specialty Retail Gap With Licensing Deal

Gap Inc. is seeking to establish a presence in the beauty market under its Gap and Banana Republic apparel labels through a partnership with fragrance marketer Inter Parfums. The firms announced an exclusive, multi-year deal for the design and manufacture of personal care products July 19

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel